Tumor Necrosis Factor (TNF) Inhibitors Market By Drug Type (Adalimumab (Humira), Certolizumab (Cimzia), Etanercept (Enbrel), Golimumab (Simponi), Infliximab (Remicade)), By Application (Crohn’s Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ulcerative Colitis, Ankylosing Spondylitis, Hidradenitis Suppurativa, Uveitis, Juvenile Arthritis) - Growth, Future Prospects & Competitive Analysis, 2018 - 2026
"Tumor Necrosis Factor (TNF) Inhibitor Market Projected to Grow With Double Digit CAGR during the Forecast Period"
Global TNF inhibitor market accounted for US$ 43,394.4 Mn in 2017 and expected to attain US$ 181,139.7 Mn in 2026 growing at a CAGR of 16.5% during the forecast period from 2018 to 2026. The TNF inhibitor market is currently driven by five approved biologics namely, adalimumab, certolizumab, etanercept, golimumab and infliximab. Adalimumab accounted for the highest market share in 2017 and expected to maintain its position throughout the forecast period from 2018 to 2026. Abbvie, Inc.’s adalimumab (Humira) claims to be the world’s bestselling drug accounting to 60% of its total revenue. With more than 100 patents, Abbvie extended adalimumab rights until 2023 in the U.S and up to October 2018 in Europe. With advent of biosimilars, the TNF inhibitor market is expected to show remunerative growth throughout the forecast period. Of the various indications TNF inhibitors are approved for, plaque psoriasis accounted for maximum market value in 2017.
Growing prevalence of Crohn’s disease and the rising demand for target-based therapies drives the growth of this segment. North America indicated highest market shares in 2017 while Asia Pacific projected to grow with fastest CAGR during the forecast period from 2018 to 2026. Rise in prevalence of autoimmune disorders, incessant research activities, structured reimbursement policies and penetration of cost-efficient biosimilars in low and middle-income economies ensured lucrativeness throughout the forecast period.
"Golimumab to exhibit fastest growth rate during the forecast period"
Golimumab projected to grow with a double digit CAGR during the forecast period from 2018 to 2026. Retention of patent rights in North America and Europe until 2024 and continuous research activities in label expansion ensures lucrativeness during the foreseen period. On October 2017, the FDA granted approval for golimumab for the treatment of adults with psoriatic arthritis and ankylosing spondylitis. Adalimumab accounted for largest market share in 2017 owing to its extensive label use in autoimmune diseases. Adalimumab solely accounted to over 40% of the overall market share in 2017. Infliximab exhibited steady growth owing to early patent expiry and its market taken over by biosimilars. Infliximab biosimilars gained market attractiveness owing to its cost efficiency and increased availability across geographies.
"Crohn’s disease to gain largest market share by 2026"
Crohn’s disease projected to grow with highest CAGR during the forecast period from 2018 to 2026. According to Centers for Disease Control and Prevention, Crohn’s disease accounted to 201 cases per 100,000 adults in 2015. This prevalence is foreseen to grow during the forecast period from 2018 to 2026 thus ensuring remunerative growth. Approval of all TNF inhibitors for the treatment of Crohn’s disease further contributes to the growth of this segment. Additionally, TNF inhibitors are the only target based treatment option for Crohn’s diseases thus holding dominancy in this segment. Plaque psoriasis accounted for largest market share in 2017 owing to increased prevalence across geographies. According to the American Academy of Dermatology, around 7.5 million people in the U.S. suffer from psoriasis, 80% of which suffer from plaque psoriasis. As other indications namely, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, uveitis, juvenile arthritis and hidradenitis suppurativa have a higher unmet need of target-based therapies, manufacturers are looking forward to promote TNF inhibitors for these indications.
"North America Dominated in 2017 and Continues This Trend Through 2026"
North America accounted for major market share of more than 40% in 2017 and projected to continue the trend throughout the forecast period. Majority of drugs retaining patent rights for longer duration in North America additionally catalyzes the market growth. Higher prevalence of autoimmune conditions such as Crohn’s disease and ulcerative colitis in U.S. and Canada contribute to the overall market growth in this region. According to press release published by Abbvie, Inc. in August 2017, around 104,000 Canadians suffer from ulcerative colitis and 4,500 new cases are diagnosed each year. The development of biosimilars in Europe is faster owing to the ease of approval of the same by European regulatory bodies. This factor thus leads to increase in availability of TNF inhibitors indicating steady growth during the forecast period. Asia Pacific exhibited fastest growth rate during the forecast period with investment from various local manufacturers in promoting biologics & biosimilars and the growing prevalence of autoimmune conditions.
"Investments in Biosimilar Development has led to Increased Competition among TNF Inhibitor Market Players"
TNF inhibitors market indicates an extensive competitive pool of players with continuous investments in research activities pertaining to label expansion or development of suitable biosimilars. The key players with their biological products namely, Abbvie, Inc.’s adalimumab, UCB S.A’s certolizumab, Amgen, Inc.’s etanercept and Janssen Biotech, Inc.’s golimumab & infliximab are expected to dominate the market until their patent expiry. Growth of biosimilars would affect the growth of existing biological drugs during the forecast period. Manufacturers across geographies are continuously investing in biosimilars thus promoting the growth of TNF inhibitors globally. Amgen, Inc. and Boehringer Ingelheim was granted FDA approval for Humira (adalimumab) in September 2016 and August 2017 respectively. Thus, post patent expiry of the major biologics, TNF inhibitor market is projected to witness extensive competition among the biosimilar market players. Acute Market Reports believes that, a new biologic drug with extensive label use and controlled pricing is expected to have an opportunity in the TNF inhibitor market.
Historical & Forecast Period
This study report provides analysis for each segment during the period from 2016 to 2026, keeping 2017 as the base year. The CAGR for each segments are also estimated for the forecast period from 2018 to 2026.
Report Scope by Segments
Tumor necrosis factor inhibitors market report includes an elaborative analysis on the current market trends and dynamics along with qualitative analysis of the global market. The report provides in depth analysis of global tumor necrosis factor inhibitors market by categorizing the market based on drug type, application and geography. The preliminary objective to publish this study is to guide healthcare professionals and market stakeholders in decision making and strategic initiatives in tumor necrosis factor inhibitors market.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2016-2026 |
| Base Year | 2017 |
| Forecast Period | 2018-2026 |
| Historical Year | 2016 |
| Unit | USD Billion |
| Segmentation |
Drug Type Segment (2016–2026; US$ Mn) |
|
Application Segment (2016–2026; US$ Mn) |
|
|
Geography Segment (2016–2026; US$ Mn) |
The current study report also includes qualitative market analysis considering factors such as key market trends, market drivers, restraints & opportunities that would enable in complete understanding of the overall tumor necrosis factor inhibitors market scenario. Furthermore, the report also includes a graphical representation of competitive landscape depicting market position of key market leaders based on their market initiative, product offerings and business strengths. Key market leaders profiled in this report are Abbvie, Inc., Amgen, Inc., Biocad Biopharmaceutical Co., Boehringer Ingelheim Pharmaceuticals, Inc., EPIRUS Biopharmaceuticals, Inc., Innovent Biologics, Inc., Janssen Biotech, Inc., Merck & Co., Inc., Novartis A.G., Pfizer, Inc., Shanghai Henlius Biotech, Inc. and UCB S.A.
Key questions answered in this report
- What are the current market trends in the tumor necrosis factor inhibitor market and valuable opportunities for industrial players?
- How does the regulatory framework affect the market dynamics?
- Which was the most successful drug that contributed maximum to market growth and what was its market share in 2017?
- How would biosimilars contribute to the lucrativeness of TNF inhibitor market during the forecast period from 2018 to 2026?
- Which disease area exhibits fastest CAGR during the forecast period from 2018 to 2026?
- Which industry player enjoyed supremacy in 2017?
- Which region encompassed maximum market share in 2017?
- What is the market trend and dynamics in emerging markets such as Japan, Latin America and Middle East & Africa?
Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Market Segmentation
1.3. Research Scope
1.4. Research Methodology
1.4.1. Phase I – Secondary Research
1.4.2. Phase II – Primary Research
1.4.3. Phase III – Expert Panel Review
1.4.4. Assumptions
Chapter 2. Executive Summary
2.1. Global TNFI Market Portraiture
2.2. TNFI Market, by Drug Type, 2017 (US$ Mn)
2.3. TNFI Market, by Application, 2017 (US$ Mn)
2.4. TNFI Market, by Geography, 2017 (US$ Mn)
Chapter 3. Global Tumor Necrosis Factor Inhibitors (TNFI) Market: Dynamics and Future Outlook
3.1. Overview
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Increased Prevalence of Autoimmune Diseases
3.2.1.2. Continuous Development of Biosimilars
3.2.2. Market Challenges
3.2.2.1. Challenge 1
3.2.3. Market Opportunities
3.2.3.1. Regulatory Support for Development of Biosimilars
3.3. Attractive Investment Proposition, by Geography, 2017
3.4. Competitive Landscape, by Key Players, 2017
Chapter 4. Global Tumor Necrosis Factor Inhibitors (TNFI) Market, by Drug Type, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. Adalimumab (Humira)
4.3. Certolizumab (Cimzia)
4.4. Etanercept (Enbrel)
4.5. Golimumab (Simponi)
4.6. Infliximab (Remicade)
4.7. Pipeline Analysis
4.7.1. Phase III Molecules (Forecast till 2026 in US$ Mn)
4.7.1.1. IBI303
4.7.1.2. HLX03
4.7.1.3. BCD-057
4.7.1.4. M923
4.7.2. Phase I & Phase II Molecules (Tabular Representation)
Chapter 5. Global Tumor Necrosis Factor Inhibitors (TNFI) Market, by Application, 2016 – 2026 (US$ Mn)
5.1. Overview
5.2. Crohn’s Disease
5.3. Rheumatoid Arthritis
5.4. Psoriatic Arthritis
5.5. Plaque Psoriasis
5.6. Ulcerative Colitis
5.7. Ankylosing Spondylitis
5.8. Hidradenitis Suppurativa
5.9. Uveitis
5.10. Juvenile Arthritis
Chapter 6. Global Tumor Necrosis Factor Inhibitors (TNFI) Market, by Geography, 2016 – 2026 (US$ Mn)
6.1. Overview
6.2. North America TNFI Market, 2016 – 2026 (US$ Mn)
6.2.1. North America TNFI Market, by Drug Type, 2016 – 2026 (US$ Mn)
6.2.2. North America TNFI Market, by Application, 2016 – 2026 (US$ Mn)
6.2.3. North America TNFI Market, by Country, 2016 – 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe TNFI Market, 2016 – 2026 (US$ Mn)
6.3.1. Europe TNFI Market, by Drug Type, 2016 – 2026 (US$ Mn)
6.3.2. Europe TNFI Market, by Application, 2016 – 2026 (US$ Mn)
6.3.3. Europe TNFI Market, by Country, 2016 – 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific TNFI Market, 2016 – 2026 (US$ Mn)
6.4.1. Asia Pacific TNFI Market, by Drug Type, 2016 – 2026 (US$ Mn)
6.4.2. Asia Pacific TNFI Market, by Application, 2016-2026 (US$ Mn)
6.4.3. Asia Pacific TNFI Market, by Country, 2016-2026 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. Rest Of Asia Pacific
6.5. Latin America TNFI Market, 2016-2026 (US$ Mn)
6.5.1. Latin America TNFI Market, by Drug Type, 2016-2026 (US$ Mn)
6.5.2. Latin America TNFI Market, by Application, 2016-2026 (US$ Mn)
6.5.3. Latin America TNFI Market, by Country, 2016-2026 (US$ Mn)
6.5.3.1. Mexico
6.5.3.2. Brazil
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) TNFI Market, 2016-2026 (US$ Mn)
6.6.1. Middle East & Africa TNFI Market, by Drug Type, 2016-2026 (US$ Mn)
6.6.2. Middle East & Africa TNFI Market, by Application, 2016-2026 (US$ Mn)
6.6.3. Middle East & Africa TNFI Market, by Region, 2016-2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of Middle East & Africa
Chapter 7. Profiles
7.1. Abbvie, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to Data Availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Amgen, Inc.
7.3. Biocad Biopharmaceutical Co.
7.4. Boehringer Ingelheim Pharmaceuticals, Inc.
7.5. EPIRUS Biopharmaceuticals, Inc.
7.6. Innovent Biologics, Inc.
7.7. Janssen Biotech, Inc.
7.8. Merck & Co., Inc.
7.9. Novartis A.G.
7.10. Pfizer, Inc.
7.11. Shanghai Henlius Biotech, Inc.
7.12. UCB S.A.
* TNFI - Tumor Necrosis Factor Inhibitors
TABLE 1 Global Tumor Necrosis Factor Inhibitors (TNFI) Market Portraiture
TABLE 2 Global TNFI Market, by Drug Type, 2016-2026 (US$ Mn)
TABLE 3 Global TNFI Market: Phase I & Phase II Pipeline Molecules
TABLE 4 Global TNFI Market, by Application, 2016-2026 (US$ Mn)
TABLE 5 Global TNFI Market , by Geography, 2016-2026 (US$ Mn)
TABLE 6 North America TNFI Market, by Drug Type, 2016-2026 (US$ Mn)
TABLE 7 North America TNFI Market, by Application, 2016-2026 (US$ Mn)
TABLE 8 North America TNFI Market, by Country, 2016-2026 (US$ Mn)
TABLE 9 Europe TNFI Market, by Drug Type, 2016-2026 (US$ Mn)
TABLE 10 Europe TNFI Market, by Application, 2016-2026 (US$ Mn)
TABLE 11 Europe TNFI Market, by Country, 2016-2026 (US$ Mn)
TABLE 12 Asia Pacific TNFI Market, by Drug Type, 2016-2026 (US$ Mn)
TABLE 13 Asia Pacific Rhythm Management Devices Market, by Application, 2016-2026 (US$ Mn)
TABLE 14 Asia Pacific TNFI Market, by Country, 2016-2026 (US$ Mn)
TABLE 15 Latin America TNFI Market, by Drug Type, 2016-2026 (US$ Mn)
TABLE 16 Latin America TNFI Market, by Application, 2016-2026 (US$ Mn)
TABLE 17 Latin America TNFI Market, by Country, 2016-2026 (US$ Mn)
TABLE 18 Middle East And Africa TNFI Market, by Drug Type, 2016-2026 (US$ Mn)
TABLE 19 Middle East And Africa TNFI Market, by Application, 2016-2026 (US$ Mn)
TABLE 20 Middle East And Africa TNFI Market, by Region, 2016-2026 (US$ Mn)
TABLE 21 Abbvie, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Amgen, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Biocad Biopharmaceutical Co. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Boehringer Ingelheim Pharmaceuticals, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 EPIRUS Biopharmaceuticals, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Innovent Biologics, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Janssen Biotech, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 Merck & Co., Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Novartis A.G. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 30 Pfizer, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 31 Shanghai Henlius Biotech, Inc. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 32 UCB S.A. : Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
FIG. 1 Market Segmentation: Global Tumor Necrosis Factor Inhibitor (TNFI) Market
FIG. 2 Research Methodology: Global TNFI Market
FIG. 3 Global TNFI Market, by Drug Type, 2017 (US$ Mn)
FIG. 4 Global TNFI Market, by Application, 2017 (US$ Mn)
FIG. 5 Global TNFI Market , by Geography, 2017 (US$ Mn)
FIG. 6 Attractive Investment Proposition, by Geography, 2017
FIG. 7 Competitive Analysis: Global TNFI Market, by Key Players, 2017
FIG. 8 Global Adalimumab Market, 2016-2026 (US$ Mn)
FIG. 9 Global Certolizumab Market, 2016-2026 (US$ Mn)
FIG. 10 Global Etanercept Market, 2016-2026 (US$ Mn)
FIG. 11 Global Golimumab Market, 2016-2026 (US$ Mn)
FIG. 12 Global Infliximab Market, 2016-2026 (US$ Mn)
FIG. 13 Global IBI303 Market, 2021-2026 (US$ Mn)
FIG. 14 Global HLX03 Market, 2021-2026 (US$ Mn)
FIG. 15 Global BCD-057 Market, 2021-2026 (US$ Mn)
FIG. 16 Global M923 Market, 2019-2026 (US$ Mn)
FIG. 17 Global TNFI Market for Crohn’s Disease Treatment, 2016-2026 (US$ Mn)
FIG. 18 Global TNFI Market for Rheumatoid Arthritis Treatment, 2016-2026 (US$ Mn)
FIG. 19 Global TNFI Market for Psoriatic Arthritis Treatment, 2016-2026 (US$ Mn)
FIG. 20 Global TNFI Market for Plaque Psoriasis Treatment, 2016-2026 (US$ Mn)
FIG. 21 Global TNFI Market for Ulcerative Colitis Treatment, 2016-2026 (US$ Mn)
FIG. 22 Global TNFI Market for Ankylosing Spondylitis Treatment, 2016-2026 (US$ Mn)
FIG. 23 Global TNFI Market for Hidradenitis Suppurativa Treatment, 2016-2026 (US$ Mn)
FIG. 24 Global TNFI Market for Uveitis Treatment, 2016-2026 (US$ Mn)
FIG. 25 Global TNFI Market for Juvenile Arthritis Treatment, 2016-2026 (US$ Mn)
FIG. 26 U.S. TNFI Market, 2016-2026 (US$ Mn)
FIG. 27 Canada TNFI Market, 2016-2026 (US$ Mn)
FIG. 28 U.K. TNFI Market, 2016-2026 (US$ Mn)
FIG. 29 Germany TNFI Market, 2016-2026 (US$ Mn)
FIG. 30 Rest of Europe TNFI Market, 2016-2026 (US$ Mn)
FIG. 31 Japan TNFI Market, 2016-2026 (US$ Mn)
FIG. 32 China TNFI Market, 2016-2026 (US$ Mn)
FIG. 33 Rest of Asia Pacific TNFI Market, 2016-2026 (US$ Mn)
FIG. 34 Mexico TNFI Market 2016-2026 (US$ Mn)
FIG. 35 Brazil TNFI Market 2016-2026 (US$ Mn)
FIG. 36 Rest of Latin America TNFI Market 2016-2026 (US$ Mn)
FIG. 37 GCC TNFI Market 2016-2026 (US$ Mn)
FIG. 38 Rest of Middle East & Africa TNFI Market 2016-2026 (US$ Mn)
Choose License
Contact Information
: sales@briskinsights.com
: +448081890034 (UK)